Subsequent studies on folic acid–based delivery of drugs to breast cancer should look at further optimizing the folate-conjugated nanoparticulate vehicles to exploit the overexpression of FR-α in almost 40 to 50% cases of human breast tumors. Here, FOLR1 is linked to breast carcinoma.